BioStem Technologies Inc. has entered into an agreement to acquire the majority assets of Auxocell Laboratories, Inc., a solid tissue processing equipment manufacturer.
 
Auxocell is the inventor and manufacturer of the Auxocell solid tissue processing device (AC:Px), a single-use, sterile processing system. The AC:Px can be used to produce a wide range of regenerative medicine products from a variety of solid tissues such as umbilical, placenta, adipose and deceased donor organs where a match is unable to be located for an organ transplant. The AC:Px allows for greater processing output and increased cell yield when producing native cellular products, minced tissue products and life changing decellularized allografts.
 
BioStem will purchase rights to all Auxocell’s assets except for the AUX003 patent family, which Auxocell will license to BioStem. Biostem will obtain 45 domestic and foreign issued patents, 11 domestic and foreign trademarks, and all remaining Auxocell equipment and inventory related to the formulation, composition and manufacturing of products derived from human placental tissues and cells.
 
Jason Matuszewski, Chief Executive Officer of BioStem said, “The acquisition will enable us to expand our intellectual property portfolio, both domestic and foreign, in the perinatal tissue space and provide additional value to our clients and shareholders. The core technology will allow us to secure the manufacturing process to isolate cells from solid tissues without the use of enzymatic digestion. The addition of Auxocell’s assets will allow us to leverage their expertise and resources to enhance our manufacturing capabilities and accelerate our growth trajectory in the marketplace.”
 
“We are pleased to announce this agreement with BioStem,” said Kyle Cetrulo Co-Founder and Chief Executive Officer of Auxocell Laboratories, Inc. “BioStem has been a customer of Auxocell’s for many years and we are excited to pass this industry leading technology to them. I look forward to seeing how BioStem utilizes the AC:Px® technology to create life changing regenerative medicine products that advance the field of cellular and tissue therapy.”